Patents by Inventor Mitsuyuki Shimada
Mitsuyuki Shimada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8129386Abstract: The present invention relates to novel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-? inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-? activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoimmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis.Type: GrantFiled: March 30, 2009Date of Patent: March 6, 2012Assignee: Bayer Pharma AktiengesellschaftInventors: Mitsuyuki Shimada, Toshiki Murata, Kinji Fuchikami, Hideki Jishita, Naoki Omori, Issei Kato, Mami Miura, Klaus Urbahns, Florian Gantner, Kevin Bacon
-
Publication number: 20090270388Abstract: The present invention relates to novel fused azolepyriimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-? inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-? activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoimmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis.Type: ApplicationFiled: March 30, 2009Publication date: October 29, 2009Applicant: Bayer Pharmaceuticals CorporationInventors: Mitsuyuki Shimada, Toshiki Murata, Kinji Fuchikami, Hideki Tsujishita, Naoki Omori, Issei Kato, Mami Miura, Klaus Urbahns, Florian Gantner, Kevin Bacon
-
Publication number: 20090149528Abstract: The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis in illnesses in people or animals, especially diseases of bacterial infection.Type: ApplicationFiled: July 2, 2008Publication date: June 11, 2009Applicant: Bayer HealthCare AGInventors: Nina Brunner, Christoph Freiberg, Thomas Lampe, Ben Newton, Michael Otteneder, Joseph Pernerstorfer, Jens Pohlmann, Guido Schiffer, Mitsuyuki Shimada, Niels Svenstrup, Rainer Endermann, Peter Nell
-
Patent number: 7544709Abstract: The invention relates to compounds of general formula (I), to a method for the production thereof, to pharmaceutical compositions containing them, and to their use in the treatment and/or prophlaxis of diseases in humans or animals, particularly bacterial infections diseases. The compounds are derivatives of the natural substances andrimide and moiramide B.Type: GrantFiled: November 7, 2002Date of Patent: June 9, 2009Assignee: Bayer Healthcare AGInventors: Nina Brunner, Christoph Freiberg, Thomas Lampe, Ben Newton, Michael Otteneder, Josef Pernerstorfer, Jens Pohlmann, Guido Schiffer, Mitsuyuki Shimada
-
Patent number: 7511041Abstract: The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-? inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-? activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis.Type: GrantFiled: September 18, 2003Date of Patent: March 31, 2009Assignee: Bayer Pharmaceuticals CorporationInventors: Mitsuyuki Shimada, Toshiki Murata, Kinji Fuchikami, Hideki Tsujishita, Naoki Omori, Issei Kato, Mami Miura, Klaus Urbahns, Florian Gantner, Kevin Bacon
-
Publication number: 20090048258Abstract: The present invention relate to a compound represented by the formula (I) or (II) wherein ring A is an optionally substituted ring (the ring should not be pyrrolidine, piperidine and piperazine), ring B is an optionally substituted aromatic ring, ring D is an optionally substituted ring, R1 and R2 are each independently a hydrogen atom or a substituent, R3 is a hydrogen atom or a C1-6 alkyl group, or R3 is bonded to ring A to form a non-aromatic ring, ring Aa is an optionally substituted aromatic hydrocarbon, Y is CH or N, Ra1 is an optionally substituted hydrocarbon group, and Ra2 and Ra3 are each independently a hydrogen atom or a substituent, or a salt thereof. The present invention provides a compound having a DGAT inhibitory activity, which is useful for the treatment or amelioration of diseases or pathologies caused by high expression or high activation of DGAT.Type: ApplicationFiled: January 31, 2006Publication date: February 19, 2009Inventors: Masaki Ogino, Yoshihisa Nakada, Mitsuyuki Shimada, Kouhei Asano, Norikazu Tamura, Minori Masago
-
Patent number: 7410986Abstract: 4-aryl pyrimidine compounds of general formula and salts thereof: wherein X is CH or N; R1 is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is hydrogen or hydroxy; R3 is hydrogen, C1-6 alkyl, etc.; R4 is hydrogen, hydroxy, halogen, amino, etc.; R5 is hydroxy, amino, carboxy, etc.; R6 is hydrogen, carbamoyl, cyano, carboxy, C1-6 alkoxycarbonyl, etc. and R7 is amino or C1-6 alkanoylamino. The compounds (I) or the salts thereof have an excellent anti-inflammatory activity and the like.Type: GrantFiled: November 19, 2001Date of Patent: August 12, 2008Assignee: Bayer AktiengesellschaftInventors: Toshiki Murata, Sachiko Sasaki, Takashi Yoshino, Yuka Ikegami, Tsutomu Masuda, Mitsuyuki Shimada, Takuya Shintani, Makoto Shimazaki, Timothy B. Lowinger, Karl B. Ziegelbauer, Kinji Fuchikami, Masaomi Umeda, Hiroshi Komura, Nagahiro Yoshida
-
Patent number: 7402683Abstract: The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis in illnesses in people or animals, especially diseases of bacterial infection.Type: GrantFiled: April 14, 2003Date of Patent: July 22, 2008Assignee: Bayer HealthCare AGInventors: Nina Brunner, Christoph Freiberg, Thomas Lampe, Ben Newton, Michael Otteneder, Josef Pernerstorfer, Jens Pohlmann, Guido Schiffer, Mitsuyuki Shimada, Niels Svenstrup, Rainer Endermann, Peter Nell
-
Patent number: 7348357Abstract: The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis of diseases in people or animals, especially diseases of bacterial infection.Type: GrantFiled: July 28, 2003Date of Patent: March 25, 2008Assignee: Bayer HealthCare AGInventors: Nina Brunner, Christoph Freiberg, Thomas Lampe, Peter Nell, Ben Newton, Michael Otteneder, Josef Pernerstorfer, Jens Pohlmann, Guido Schiffer, Mitsuyuki Shimada, Niels Svenstrup, Rainer Endermann
-
Patent number: 7129255Abstract: This application relates to compounds of the formula wherein the groups R1–R6 are as defined in the specification and claims, and to a pharmaceutical composition containing the same, and to a method of using the same in treatment of cardiovascular disorders.Type: GrantFiled: March 25, 2002Date of Patent: October 31, 2006Assignee: Bayer AktiengesellschaftInventors: Ulrich Rosentreter, Thomas Krämer, Andrea Vaupel, Walter Hübsch, Nicole Diedrichs, Thomas Krahn, Klaus Dembowsky, Johannes-Peter Stasch, Mitsuyuki Shimada
-
Publication number: 20060217373Abstract: Compounds of the formula (I) a process for their preparation and their use as medicaments are described.Type: ApplicationFiled: May 30, 2006Publication date: September 28, 2006Applicant: Bayer Healthcare AGInventors: Ulrich Rosentreter, Thomas Kramer, Mitsuyuki Shimada, Walter Hubsch, Nicole Diedrichs, Thomas Krahn, Kerstin Henninger, Johannes-Peter Stasch, Ralf Wischnat
-
Patent number: 7109218Abstract: Compounds of the formula (I) a process for their preparation and their use as medicaments are described.Type: GrantFiled: November 28, 2002Date of Patent: September 19, 2006Assignee: Bayer HealthCare AGInventors: Ulrich Rosentreter, Thomas Krämer, Mitsuyuki Shimada, Walter Hübsch, Nicole Diedrichs, Thomas Krahn, Kerstin Henninger, Johannes-Peter Stasch, Ralf Wischnat
-
Publication number: 20060205676Abstract: Pyrimidine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di (C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents hydrogen, —CR31R32R33; R4 is hydrogen, carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.Type: ApplicationFiled: September 30, 2005Publication date: September 14, 2006Applicant: Bayer AktiengesellschaftInventors: Toshiki Murata, Masaomi Umeda, Sachiko Sakakibara, Takashi Yoshino, Hiroki Sato, Tsutomu Masuda, Yuji Koriyama, Mitsuyuki Shimada, Takuya Shintani, Hiroshi Kadono, Timothy Lowinger, Karl Ziegelbauer, Kinji Fuchikami, Hiroshi Komura
-
Publication number: 20060178369Abstract: The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis in illnesses in people or animals, especially diseases of bacterial infection.Type: ApplicationFiled: April 14, 2003Publication date: August 10, 2006Inventors: Nina Brunner, Christoph Freiberg, Thomas Lampe, Ben Newton, Michael Otteneder, Josef Pernerstorfer, Jens Pohlmann, Guido Schiffer, Mitsuyuki Shimada, Niels Svenstrup, Rainer Endermann
-
Publication number: 20060173040Abstract: The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis of diseases in people or animals, especially diseases of bacterial infection.Type: ApplicationFiled: July 28, 2003Publication date: August 3, 2006Applicant: Bayer HealthCare AGInventors: Nina Brunner, Christoph Freiberg, Thomas Lampe, Peter Nell, Ben Newton, Michael Otteneder, Josef Pernerstorfer, Jens Pohlmann, Guido Schiffer, Mitsuyuki Shimada, Niels Svenstrup, Rainer Endermann
-
Patent number: 7078417Abstract: This application relates to pyridine derivatives having the general structure in which the several variables are as defined in the specification and claims, and to a process for preparing these compounds, a pharmacutical composition containing such compounds, and a method for using these materials for treatment of stable and unstable angina pectoris and atrial fibrillation.Type: GrantFiled: March 19, 2002Date of Patent: July 18, 2006Assignee: Bayer AktiengesellschaftInventors: Ulrich Rosentreter, Thomas Krämer, Andrea Vaupel, Walter Hübsch, Nicole Diedrichs, Thomas Krahn, Klaus Dembowsky, Johannes-Peter Stasch, Mitsuyuki Shimada
-
Publication number: 20060128732Abstract: The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-? inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-? activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis.Type: ApplicationFiled: September 18, 2003Publication date: June 15, 2006Applicant: Bayer Pharmaceuticals CorporationInventors: Mitsuyuki Shimada, Toshiki Murata, Kinji Fuchikami, Hideki Tsujishita, Naoki Omori, Issei Kato, Mami Miura, Klaus Urbahns, florian Gantner, Kevin Bacon
-
Patent number: 7045631Abstract: Compounds of the formula (I) a process for preparing them, and their use as medicaments are described.Type: GrantFiled: July 3, 2002Date of Patent: May 16, 2006Assignee: Bayer AktiengesellschaftInventors: Ulrich Rosentreter, Thomas Kramer, Mitsuyuki Shimada, Walter Hubsch, Nicole Diedrichs, Thomas Krahn, Kerstin Henninger, Johannes-Peter Stasch
-
Publication number: 20060100246Abstract: This invention is to provide a process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs and salts thereof, comprising the reaction shown by the following scheme. The ester analogs can be prepared in one pot, and in good yield by using tertiary alkyl cyanoacetate. Furthermore, the method is useful for preparing derivatives of various analogs of the ester, e.g. alkyl substituted and aryl substituted analogs.Type: ApplicationFiled: September 30, 2005Publication date: May 11, 2006Applicant: Bayer AktiengesellschaftInventors: Toshiki Murata, Masaomi Umeda, Sachiko Sakakibara, Takashi Yoshino, Hiroki Sato, Tsutomu Masuda, Yuji Koriyama, Mitsuyuki Shimada, Takuya Shintani, Hiroshi Kadono, Timothy Lowinger, Karl Ziegelbauer, Kinji Fuchikami, Hiroshi Komura
-
Patent number: 6984649Abstract: Pyridine compounds of general formula: wherein —R1 represents in which R11 is hydrogen, C1-6 alkyl, halogen, hydroxy, C1-12 alkoxy, nitro, amino, C1-6 alkylsulfonylamino, C1-6 alkoxycarbonyl, C1-6 alkylamino, di (C1-6 alkyl)amino, C1-6 alkanoylamino, phenyl C1-6 alkylamino, phenylsulfonylamino, or —O—(CH2)n—R111; R2 represents hydrogen or halogen; R3 represents 1.2.3.6-tetrahydro-pyridine, or —CR31R32R33 wherein R31 represents H or C1-6 alkyl and R32 and R33 are joined to form a 5-8 membered saturated ring optionally containing up to three heteroatoms; R4 is carbamoyl, CN, carboxyl, etc.; R5 is amino, C1-6 alkylamino, di C1-6 alkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.Type: GrantFiled: March 28, 2003Date of Patent: January 10, 2006Assignee: Bayer AktiengesellschaftInventors: Toshiki Murata, Masaomi Umeda, Sachiko Sakakibara, Takashi Yoshino, Hiroki Sato, Tsutomu Masuda, Yuji Koriyama, Mitsuyuki Shimada, Takuya Shintani, Hiroshi Kadono, Timothy B. Lowinger, Karl B. Ziegelbauer, Kinji Fuchikami, Hiroshi Komura